% latex table generated in R 4.4.1 by xtable 1.8-4 package
% Wed Dec 10 17:36:05 2025

{
\newgeometry{left=1.5cm, right=1.5cm, top=2cm, bottom=1.5cm}
\captionsetup{width=1\textheight, font=scriptsize, skip=7pt}

\begin{landscape}
  % \singlespacing
  \pagestyle{empty}
  \scriptsize
  \begin{ThreePartTable}
    \begin{TableNotes}
      \item[1] Study name is composed of the lead author and year of publication.
      \item[2] Refer to the supplementary material of the publication for allometric dosing table\cite{mbui2019}.
      \item[3] SSG tested and dispensed by International Dispensary Association, The Netherlands; manufactored by Albert David Ltd, India.
      \item[4] For both arms in Veeken 2010, Ritmeijer 2001, and Ritmeijer 2006, if positive initial test--of--cure, treatment would continue with SSG, including if previously taking MF, until two subsequent consecutive tests of cure, performed weekly, were negative.
      \item[5] Actual dosing ranged from 2.0--3.33 mg/kg/day after rounding to nearest 10mg tablets; full regimen described in publication\cite{wasunna2016}
    \end{TableNotes}

    \begin{longtable}[c]{L{1cm} L{4cm} L{1cm} L{1.5cm} L{3.5cm} L{2.5cm} L{3.7cm} L{1cm} L{1cm} L{1cm} L{1.3cm}}
      \caption{Key characteristics of included studies from East Africa, ordered by lead author and year of publication/protocol. -: not reported; BD: twice daily (bis die); D: Day(s); IM: intramuscular; IV: intravenous; LAMB: Liposomal amphotericin B (Gilead formulation); MF: Miltefosine; mg/kg: milligrams per kilogram; OD: once daily (omni die); PO: per os (oral); PM: Paromomycin; SSG: Sodium stibogluconate; \label{tab:ea_study}}                                                                                                                                                                                                                                                                                                                                                                                                               \\
      \toprule
      Study\tnote{1}                     & Title                                                                                                                                                                                       & Journal                  & Sponsor/ funding            & Location(s)                                                                                                                                                                        & Study design                                                                        & Study arm(s)\tnote{4}                                                                                                                                                                                                       & Age (years) & Study period & n (model) & Relapses (\%) \\ \midrule
      \endfirsthead

      \caption[]{continued}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \\
      \toprule
      Study\tnote{1}                     & Title                                                                                                                                                                                       & Journal                  & Sponsor/ funding            & Location(s)                                                                                                                                                                        & Study design                                                                        & Study arm(s)\tnote{4}                                                                                                                                                                                                       & Age (years) & Study period & n (model) & Relapses (\%) \\ \midrule
      \endhead

      \multicolumn{11}{r}{\textit{continued on next page}}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        \\
      \endfoot

      \insertTableNotes
      \endlastfoot

      Hailu 2010\cite{hailu2010}         & Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial                                                 & PLoS Negl Trop Dis       & DNDi/MSF                    & 5 centres: Ethiopia (Gondar University Hospital, Arba Minch Hospital); Sudan (MSF Treatment Centre, Um el Khjer; Ministry of Health Hospital, Kassab); Kenya (CCR, KEMRI, Nairobi) & Multicentre, open-label, randomised trial                                           & (1) SSG, 20 mg/kg, IV or IM, OD, 30 D; (2) PM, 15 mg/kg, IM, OD, 21 D; (3) Combination of PM and SSG, same dose, frequency and route, 17 D                                                                                  & 4--60       & 2004--2008   & 289       & 21 (7.3)      \\ \midrule
      Khalil 2014\cite{khalil2014}       & Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial                                          & PLoS Negl Trop Dis       & DNDi (multiple funders)     & 3 centres: Ethiopia (Gondar University Hospital, Arba Minch Hospital); Sudan (Ministry of Health Hospital, Kassab)                                                                 & Multicentre, open-label, non-inferiority, randomised trial with adaptive design     & LAMB, IV, either single dose at (1) 7.5mg/kg; (2) 10 mg/kg; (3) 12.5 mg/kg; (4) 15 mg/kg, or multiple dose at (5) 3 mg/kg, OD, D1-5, 14, 21 (total 21 mg/kg)                                                                & $\geq$ 4    & 2009--2011   & 92        & 11 (12.0)     \\ \midrule
      Mbui 2019\cite{mbui2019}           & Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial & Clin Infect Dis          & DNDi (multiple funders)     & 2 clinical sites: Kachelibra, West Pokot County, Kenya; Amudat, Karamoja sub-region, Uganda                                                                                        & Open-label, phase II, clinical trial                                                & (1) MF, allometric dosing according to sex, height, and weight, BD, PO, 28 D\tnote{2}                                                                                                                                       & 4--12       & 2015--2016   & 29        & 2 (6.9)       \\ \midrule
      Musa 2010\cite{musa2010}           & Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study                                                                              & PLoS Negl Trop Dis       & DNDi (multiple funders)     & Ministry of Health Hospital, Kassab, Sudan                                                                                                                                         & Open-label, open-label, phase II, randomised, dose-finding study                    & (1) PM, 15 mg/kg, IM, OD, 28 D; (2) PM, 20 mg/kg, IM, OD, 21 D                                                                                                                                                              & 4--60       & 2005--2006   & 40        & 8 (20.0)      \\ \midrule
      Musa 2012\cite{musa2012}           & Sodium stibogluconate (SSG) \& paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial                                             & PLoS Negl Trop Dis       & DNDi/MSF (multiple funders) & 6 centres: 5 centres described in Khalil 2014 (above) and Amudat Hospital, Uganda.                                                                                                 & Multicentre, open-label, parallel-arm, randomised trial                             & (1) SSG, 20 mg/kg, IV or IM, OD, 30 D; (2) PM, 20 mg/kg, IM, OD, 21 D; (3) combination of SSG, 20 mg/kg, IV or IM, OD, 17 D and PM, 15 mg/kg, IM, OD, 17 D                                                                  & 4--60       & 2004--2010   & 638       & 30 (4.7\%)    \\ \midrule
      Ritmeijer 2001\cite{ritmeijer2001} & Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome                                                & Trans R Soc Trop Med Hyg & MSF                         & Temporary MSF treatment centre, Densha, Ethiopia                                                                                                                                   & Open-label, pseudo-randomised controlled trial                                      & (1) SSG (generic)\tnote{3}, 20 mg/kg, IM, 30 D; (2) SSG (Pentostam, GlaxoWellcome), 20 mg/kg, IM, 30 D                                                                                                                      & all         & 1998--1999   & 112       & 1 (0.9)       \\ \midrule
      Ritmeijer 2006\cite{ritmeijer2006} & A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection                              & Clin Infect Dis          & MSF                         & 2 centres in Ethiopia: Humera Hospital, Mycadra Health Center                                                                                                                      & Open-label, randomised controlled trial                                             & (1) SSG, 20 mg/kg/day, IM, OD, 30 D (extended if HIV positive); (2) MF, 100 mg/day, PO, OD, 28 D                                                                                                                            & $\geq$ 15   & 2003--2005   & 248       & 6 (2.4)       \\ \midrule
      Veeken 2000\cite{veeken2000}       & A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan                      & Trop Med Int Health      & MSF                         & 2 MSF treatment centres in Gedaref State, Sudan: Um Kuraa, Kassab                                                                                                                  & Open-label, pseudo-randomised controlled trial                                      & (1) SSG (generic)\tnote{3}, 20 mg/kg, IM, 30 D; (2) SSG (Pentostam, GlaxoWellcome), 20 mg/kg, IM, 30 D                                                                                                                      & all         & 1998--1999   & 465       & 4 (0.9)       \\ \midrule
      Wasunna 2016\cite{wasunna2016}     & Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.         & PLoS Negl Trop Dis       & DNDi (multiple funders)     & 3 centres: Kenya (Kimalel Health Centre); Sudan (Dooka Hospital and Ministry of Health Hospital, Kassab)                                                                           & Phase II, open-label, non-comparative randomised trial (adaptive-sequential design) & (1) Combination of LAMB, 10 mg/kg, IV, single dose, D1 and SSG, 20 mg/kg, IM, OD, D2-11; (2) Combination of LAMB, 10 mg/kg, IV, single dose, D1, and MF, 2.5 mg/kg, PO, OD, D2-11; (3) MF\tnote{5}, 2.5 mg/kg, PO, OD, 28 D & 7--60       & 2010--2012   & 138       & 16 (11.6)     \\ \bottomrule
    \end{longtable}
  \end{ThreePartTable}
\end{landscape}
}
\pagestyle{fancy}
\restoregeometry